File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Altered bile acid and coproporphyrin-I disposition in patients with autosomal dominant polycystic kidney disease

TitleAltered bile acid and coproporphyrin-I disposition in patients with autosomal dominant polycystic kidney disease
Authors
Keywordschronic kidney disease
drug interactions
drug transporters
hepatotoxicity
mass spectrometry
Issue Date1-Feb-2025
PublisherWiley
Citation
British Journal of Clinical Pharmacology, 2025, v. 91, n. 2, p. 353-364 How to Cite?
AbstractAims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non-clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug-induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin-I (CP-I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B-mediated DDI risk in humans. In this clinical observational cohort-comparison study, bile acid profiles and CP-I concentrations in healthy volunteers and patients with ADPKD were compared. Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP-I concentrations, were quantified by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3-fold) and taurine-conjugated (2.8-fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5-, 2.9-, 2.8-, 1.6-, 1.7- and 2.7-fold, respectively) in patients with ADPKD. Furthermore, serum CP-I concentrations were elevated and the renal clearance of CP-I was reduced in patients with ADPKD compared to healthy volunteers. Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP-I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers.
Persistent Identifierhttp://hdl.handle.net/10722/358210
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 1.046
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTiley, Jacqueline B-
dc.contributor.authorBeaudoin, James J-
dc.contributor.authorDerebail, Vimal K-
dc.contributor.authorMurphy, William A-
dc.contributor.authorPark, Christine C-
dc.contributor.authorVeeder, Justin A-
dc.contributor.authorTran, Lana-
dc.contributor.authorBeers, Jessica L-
dc.contributor.authorJia, Wei-
dc.contributor.authorStewart, Paul W-
dc.contributor.authorBrouwer, Kim LR-
dc.date.accessioned2025-07-26T00:30:22Z-
dc.date.available2025-07-26T00:30:22Z-
dc.date.issued2025-02-01-
dc.identifier.citationBritish Journal of Clinical Pharmacology, 2025, v. 91, n. 2, p. 353-364-
dc.identifier.issn0306-5251-
dc.identifier.urihttp://hdl.handle.net/10722/358210-
dc.description.abstractAims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non-clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug-induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin-I (CP-I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B-mediated DDI risk in humans. In this clinical observational cohort-comparison study, bile acid profiles and CP-I concentrations in healthy volunteers and patients with ADPKD were compared. Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP-I concentrations, were quantified by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3-fold) and taurine-conjugated (2.8-fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5-, 2.9-, 2.8-, 1.6-, 1.7- and 2.7-fold, respectively) in patients with ADPKD. Furthermore, serum CP-I concentrations were elevated and the renal clearance of CP-I was reduced in patients with ADPKD compared to healthy volunteers. Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP-I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers.-
dc.languageeng-
dc.publisherWiley-
dc.relation.ispartofBritish Journal of Clinical Pharmacology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectchronic kidney disease-
dc.subjectdrug interactions-
dc.subjectdrug transporters-
dc.subjecthepatotoxicity-
dc.subjectmass spectrometry-
dc.titleAltered bile acid and coproporphyrin-I disposition in patients with autosomal dominant polycystic kidney disease-
dc.typeArticle-
dc.identifier.doi10.1111/bcp.16221-
dc.identifier.scopuseid_2-s2.0-85204722025-
dc.identifier.volume91-
dc.identifier.issue2-
dc.identifier.spage353-
dc.identifier.epage364-
dc.identifier.eissn1365-2125-
dc.identifier.isiWOS:001321285300001-
dc.identifier.issnl0306-5251-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats